Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP525165.RAFELhBjb8DF9KRk1C6EGrhcExjuY3CgVWnNWEayHuB_g130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP525165.RAFELhBjb8DF9KRk1C6EGrhcExjuY3CgVWnNWEayHuB_g130_assertion type Assertion NP525165.RAFELhBjb8DF9KRk1C6EGrhcExjuY3CgVWnNWEayHuB_g130_head.
- NP525165.RAFELhBjb8DF9KRk1C6EGrhcExjuY3CgVWnNWEayHuB_g130_assertion description "[In addition, immunohistochemical studies on mouse tumors injected with cisplatin or paclitaxel treated residual cells displayed higher staining for the proliferative antigen Ki67, oncogeneic CA125, epithelial E-cadherin as well as cancer stem cell markers such as Oct4 and CD117, compared to mice injected with control untreated cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP525165.RAFELhBjb8DF9KRk1C6EGrhcExjuY3CgVWnNWEayHuB_g130_provenance.
- NP525165.RAFELhBjb8DF9KRk1C6EGrhcExjuY3CgVWnNWEayHuB_g130_assertion evidence source_evidence_literature NP525165.RAFELhBjb8DF9KRk1C6EGrhcExjuY3CgVWnNWEayHuB_g130_provenance.
- NP525165.RAFELhBjb8DF9KRk1C6EGrhcExjuY3CgVWnNWEayHuB_g130_assertion SIO_000772 23537295 NP525165.RAFELhBjb8DF9KRk1C6EGrhcExjuY3CgVWnNWEayHuB_g130_provenance.
- NP525165.RAFELhBjb8DF9KRk1C6EGrhcExjuY3CgVWnNWEayHuB_g130_assertion wasDerivedFrom befree-20150227 NP525165.RAFELhBjb8DF9KRk1C6EGrhcExjuY3CgVWnNWEayHuB_g130_provenance.
- NP525165.RAFELhBjb8DF9KRk1C6EGrhcExjuY3CgVWnNWEayHuB_g130_assertion wasGeneratedBy ECO_0000203 NP525165.RAFELhBjb8DF9KRk1C6EGrhcExjuY3CgVWnNWEayHuB_g130_provenance.